ATE523497T1 - Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen - Google Patents

Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Info

Publication number
ATE523497T1
ATE523497T1 AT07847181T AT07847181T ATE523497T1 AT E523497 T1 ATE523497 T1 AT E523497T1 AT 07847181 T AT07847181 T AT 07847181T AT 07847181 T AT07847181 T AT 07847181T AT E523497 T1 ATE523497 T1 AT E523497T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
obesitas
hydroxyphenyl
new
Prior art date
Application number
AT07847181T
Other languages
English (en)
Inventor
Preben Houlberg Olesen
Anders Klarskov Petersen
Flemming Elmelund Nielsen
Lise Brown Christiansen
Holger Claus Hansen
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE523497T1 publication Critical patent/ATE523497T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07847181T 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen ATE523497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601486 2006-11-15
PCT/EP2007/062409 WO2008059026A1 (en) 2006-11-15 2007-11-15 Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes

Publications (1)

Publication Number Publication Date
ATE523497T1 true ATE523497T1 (de) 2011-09-15

Family

ID=39052661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07847181T ATE523497T1 (de) 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Country Status (5)

Country Link
US (1) US7915299B2 (de)
EP (1) EP2097388B1 (de)
AT (1) ATE523497T1 (de)
CA (1) CA2669884A1 (de)
WO (1) WO2008059026A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
US20100249161A1 (en) * 2006-11-15 2010-09-30 Anders Klarskov Petersen 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
CA2669874A1 (en) * 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
CN102617478B (zh) * 2011-01-31 2015-07-15 华东理工大学 苯并咪唑、噁唑和噻唑衍生物的合成及其应用
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20150039551A (ko) * 2013-10-02 2015-04-10 제이에스알 가부시끼가이샤 경화성 조성물, 경화막 및 그의 형성 방법, 그리고 화합물
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
EP3344619B1 (de) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethylderivate
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
ES2830447T3 (es) 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo
EP3596060B1 (de) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG Neue bicyclische verbindungen als atx-inhibitoren
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3269955A (en) 1963-05-10 1966-08-30 American Cyanamid Co Method for emitting fluorescent light using fluorescent quinazolones
US3526627A (en) 1969-06-05 1970-09-01 American Cyanamid Co Method for preparation of quinazolones
JPS6025984A (ja) 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
US5240962A (en) 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
CZ120398A3 (cs) 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
AU4345297A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
EP0981526B1 (de) 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1998045292A1 (en) 1997-12-02 1998-10-15 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
EP1123269A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
EP1123297A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Verbindungen, ihre herstellung und verwendung
AU6190199A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
WO2000023425A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
IL145958A0 (en) 1999-04-16 2002-07-25 Reddy Research Foundation Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
HUP0200807A3 (en) 1999-04-20 2003-03-28 Novo Nordisk As Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EP1171431A1 (de) 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre anwendung und ihre verwendung
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542246A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
EP1575575B1 (de) 2002-11-08 2010-05-19 High Point Pharmaceuticals, LLC Sichere chemische entkuppler zur behandlung von fettsucht
WO2004065370A1 (en) 2003-01-23 2004-08-05 Crystalgenomics, Inc. Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
AU2004292536A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. Methods for producing olfactory GPCRS
EP1689700A1 (de) 2003-11-25 2006-08-16 Novo Nordisk A/S Neue salicylsäure anilide
EP1758856A2 (de) 2004-05-04 2007-03-07 Novo Nordisk A/S Indolderivate zur behandlung von obesitas
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
US7705157B2 (en) * 2004-12-16 2010-04-27 Symyx Solutions, Inc. Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
CA2669874A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US20100249161A1 (en) 2006-11-15 2010-09-30 Anders Klarskov Petersen 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes

Also Published As

Publication number Publication date
EP2097388A1 (de) 2009-09-09
CA2669884A1 (en) 2008-05-22
WO2008059026A1 (en) 2008-05-22
US7915299B2 (en) 2011-03-29
US20100063122A1 (en) 2010-03-11
EP2097388B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
DE602007009865D1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MA32811B1 (fr) Nouveaux composés
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201100007A1 (ru) Производные хиноксалиндиона
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201170521A1 (ru) Новые соединения
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
EA201070423A1 (ru) Диарильные соединения оксадиазолов
TN2011000627A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
ATE542531T1 (de) Nitrofuran-verbindungen zur behandlung von krebs und angiogenese
NO20082096L (no) Azaindol-2-karboksamidderivativer
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
NO20055741L (no) Nye kjemiske forbindelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties